Abstract
The pathogenic mechanisms in Behçet’s syndrome are largely unknown. An autoantigen role for human leukocyte antigen B51 has been proposed. The reasons behind the thrombophilia are also not clear. Endothelial pathology could be the main culprit. The recently proposed association between familial Mediterranean fever and Behçet’s syndrome might not be well founded. The long-term prognosis is more guarded among the young and among males. However, the disease burns out in many cases. Clinicians are getting better at management, and have better understanding of the old drugs, such as colchicine, and have new and potent drugs like tumor necrosis factor-alpha inhibitors.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Yazici H: Behçet’s syndrome: where do we stand? Am J Med 2002, 112:75–76.
Direskeneli H: dBehçet’s disease: infectious etiology, new autoantigens, and HLA-B51. Ann Rheum Dis 2001, 996–1002. A comprehensive discussion of pathogenic mechanisms with emphasis on immunology.
Gül A: Behçet’s disease: an update on the pathogenesis. Clin Exp Rheumatol 2001, 19(suppl):6–12. A comprehensive discussion of pathogenic mechanisms with emphasis on genetics.
Gul A, Hajeer AH, Worthington J, et al.: Linkage mapping of a novel susceptibility locus for Behçet’s disease to chromosome 6p22-23. Arthritis Rheum 2001, 44:2693–2696.
Gul A, Ozbek A, Ozturk C, et al.: Coagulation factor V gene mutations increases the risk of venous thrombosis in Behçet’s disease. Br J Rheumatol 1996, 35:1178–1180.
Verity DH, Vaughan RW, Madanat W, et al.: Factor V Leiden is associated with ocular involvement in Behçet’s disease. Am J Ophthalmol 1999, 128:352–356.
Lesprit P, Wechsler B, Piette JC: Activated protein C resistance caused by V Arg 506/Gln mutation has no role in the thrombotic manifestations of Behçet’s disease. Ann Rheum Dis 1995, 54:860.
Gul A, Aslantas AB, Tekinay T, et al.: Procoagulant mutations and venous thrombosis in Behçet’s disease. Rheumatology (Oxford) 1999, 38:1298–1299.
Espinosa G, Font J, Tassies D, et al.: Vascular involvement in Behçet’s disease: relationship with thrombophilic factors, coagulation activitation and thrombomodulin. Am J Med 2002, 112:37–43. A detailed and controlled study of thrombophilia in BS. The bottom line is that the results are "negative" for any specific cause.
Chambers JC, Haskard DO, Kooner JC: Vascular endothelial function and oxidative stress mechanisms in patients with Behçet’s syndrome. J Am Coll Cardiol 2001, 37:517–520.
Aksu K, Turgan S, Oksel F, et al.: Hyperhomocysteinemia in Behçet’s disease. Rheumatology (Oxford) 2001, 40:687–690.
Korkmaz C, Bozan B, Kosar M, et al.: Is there an association of plasma homocysteine levels with vascular involvement in patients with Behçet’s syndrome? Clin Exp Rheumatol 2002, 20:S30-S34.
Tunc R, Ozbakir F, Caglayan A, et al.: Absence of ANCA in Behçet’s syndrome with large vessel involvement. Angiology 2003, In press.
Tokay S, Direskeneli H, Yurdakul S, Akoglu T: Anticardiolipin antibodies in Behçet’s disease: a reassessment. Rheumatology (Oxford) 2001, 40:192–195. Almost a final word that anticardiolipin antibodies are not in the picture in BS.
Krause I, Monselise G, Milo G, Weinberger A: Anti Saccharomyces antibodies: a novel serologic marker for Behçet’s disease. Clin Exp Rheumatol 2002, 20(suppl):S21-S24.
Chaurel JL, Diemert MC, Musset L, et al.: Absence of antisaccharomyces cerevisae antibodies (ASCA) in BD. Abstract presented at the 10th International Conference on Behçet’s Disease. Berlin, June 27–29, 2002.
Mor F, Weinberger A, Cohen IR: Identification of alpha tropomyosin as a target self-antigen in Behçet’s syndrome. Eur J Immunol 2002, 32:356–365.
Kurhan-Yavuz S, Direskeneli H, Bozkurt N, et al.: Anti -MHC autoimmunity in Behçet’s disease: T cell responses to an HLA-B derived peptide cross-reactive with retinal S antigen in patients with uveitis. Clin Exp Immunol 2000, 120:162–166. A first time proposal for autoantigens being important in pathogenesis. These antigens are the retinal S antigen and the HLA-51 molecule.
Demirkesen C, Tüzüner N, Mat C, et al.: Clinicopathological evaluation of nodular lesions of Behçet syndrome. Am J Clin Pathol 2001, 116:341–346.
Kim B, LeBoit PE: Histopathologic features of erythema nodosum like lesions of in Behçet’s disease: a comparison with erythema nodosum focusing on the role of vasculitis. Am J Dermatopathol 2000, 22:379–390.
Diri E, Mat C, Hamuryudan V, et al.: Papulopustular lesions are seen more frequently in patients with Behçet’s syndrome who have arthritis: a controlled and masked study. Ann Rheum Dis 2001, 60:1074–1076. Report of a controlled clinical observation which proposes that the associaiton of acne arthritis might have implications in pathogenesis. The observations confirmed by a later study (ref. 22) from the same groupç.
Tunc R, Keyman E, Melikoglu M, et al.: Target organ associations in Turkish patients with Behçet’s disease: a cross sectional study by exploratory factor analysis. J Rheumatol 2002, 29:2393–2396.
Yurdakul S, Tuzuner N, Yurdakul V, Yazici H: Gastrointestinal involvement in Behçet’s syndrome: a controlled study. Ann Rheum Dis 1996, 55:208–210.
Lee CR, Kim WH, Cho YS, et al.: Colonoscopic findings in Behçet’s disease. Inflamm Bow Dis 2001, 7:243–249.
Korman U, Mihmanl I, Soylu N, et al.: Enteroclysis findings of intestinal Behçet’s disease: a comparative study with Crohn’s disease. Abdom Imaging 2003, In press.
Birlik M, Tunca M, Hizli N, et al.: Co-existence of familial Mediterranean fever sacroiliitis and Behçet’s disease: a rare occurrence. Clin Rheumatol 1998, 17:397–399.
Schwartz T, Langevitz P, Zemer D, et al.: Behçet’s disease in familial Mediterranean fever: characterization of the association between the two diseases. Semin Arthritis Rheum 2000, 29:286–295.
Yurdakul S, Mat C, Ozyazgan Y, et al.: A double blind trial of colchicine in Behçet’s syndrome. Arthritis Rheum 2001, 44:2686–2692. A 2-year, double blind study of the most commonly used drug in BS. The results show that colchicine is particularly useful in arthritis and eryhema nodosum in each gender and the genital lesions among females.
Ben-Chetrit E, Ureili-Shoval S, Calko D, et al.: Molecular diagnosis FMF: lessons from a study of 446 unrelated individuals. Clin Exp Rheumatol 2002, 20(suppl):S25-S29.
Gumucio DL, Diaz A, Schaner P, et al.: Fire and ICE: the role of pyrin domain-containing proteins in inflammation and apoptosis. Clin Exp Rheumatol 2002, 20(suppl):S455-S53. An excellent and up to date discussion of "pyrin" in inflammation with due emphasis on how it relates to apoptosis.
Touitou I, Magne X, Molinari N, et al.: MEFV mutations in Behçet’s disease. Hum Mutat 2000, 16:271–272.
Rabinovich A, Livneh A, Langevitz P, et al.: Mediterranean fever gene (MEFV) mutations and rheumatoid arthritis: a severe combination. Clin Exp Rheumatol 2002, 20(suppl):S73.
Ozdogan H, Melikoglu M, Altiparmak MR, et al.: Increased MEFV gene point mutations in secondary amyloidosis among Turkish patients. Abstract presented at the 10th International Conference on Behçet’s Disease. Berlin, June 27–29, 2002.
Shinar Y, Livneh A, Villa Y, et al.: MEFV mutations and autoimmune diseases: a severe combination. Clin Exp Rheumatol 2002, 20(suppl):S75.
Ben-Chetrit E, Cohen R, Chajek-Shaul T: Familial Mediterranean fever and Behçet’s disease: are they associated? J Rheumatol 2002, 29:530–534. Report from a center with vast experience in FMF. Data suggest that researchers must not hastily accept that FMF and BS are related.
Tunc R, Uluhan A, Mel koglu M, et al.: A reassessment of the International Study Group criteria for the diagnosis (classification) of Behçet’s syndrome. Clin Exp Rheumatol 2001, 19(suppl):S45-S47.
Kural-Seyahi E, Fresko I, Seyahi N, et al.: The long term mortality and morbidity of Behçet syndrome: a two decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003, 82:60–76. Thus far the most comprehensive survey of prognosis in BS. The young males definitely have less favorable prognosis and the disease eventually burns out in many cases.
Kaklamani VG, Kaklamanis PG: Treatment of Behçet’s disease: an update. Semin Arthritis Rheum 2001, 30:299–312.
Aktulga E, Altac M, Muftuoglu A, et al.: A double blind study of colchicine in Behçet’s disease. Haematologica 1980, 65:399–402.
Alpsoy E, Durusoy C, Yilmaz E, et al.: Interferon alfa 2a in Behçet’s disease: a randomized placebo controlled and double blind study. Arch Dermatol 2002, 138:467–471.
Sharquie KE, Najim RF, Abu-Raghif AR: Dapsone in Behçet’s disease: a double blind, placebo-controlled, crossover study. J Dermatol 2002, 29:267–269.
Sfikakis PP, Theodossiadis PG, Katsiari CG, et al.: Effect of infliximab on sight-threatening panuveitis in Behçet’s disease. Lancet 2001, 358:295–296.
Travis SP, Czajkowski M, McGovern DP, et al.: Treatment of intestinal Behçet’s disease with chimeric tumor necrosis factor alpha antibody. Gut 2001, 49:725–728.
Melikoglu M, Fresko I, Mat C, et al.: A double blind placebo controlled trial of etanercept on the mucocutaneous lesions of Behçet’s syndrome. Abstract presented at the 10th International Conference on Behçet’s Disease. Berlin, June 27–29, 2002.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yazici, H. Behçet’s syndrome: An update. Curr Rheumatol Rep 5, 195–199 (2003). https://doi.org/10.1007/s11926-003-0066-9
Issue Date:
DOI: https://doi.org/10.1007/s11926-003-0066-9